SJ Berwin has won the lead role on a French-American pharma deal, strengthening its relationship with French drug company NicOx. The City law firm won the mandate to advise NYSE Euronext Paris-listed NicOx as it bought back rights to develop and market an innovative eye disease drug from US pharma giant Pfizer.
September 09, 2009 at 06:00 AM
1 minute read
The original version of this story was published on Legalweek
SJ Berwin has won the lead role on a French-American pharma deal, strengthening its relationship with French drug company NicOx.
The City law firm won the mandate to advise NYSE Euronext Paris-listed NicOx as it bought back rights to develop and market an innovative eye disease drug from US pharma giant Pfizer.
Presented by BigVoodoo
Celebrating achievement, excellence, and innovation in the legal profession in the UK.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Associate attorney position at NJ Immigration Law firm: Leschak & Associates, LLC, based in Freehold, NJ, is looking for a full time ass...
Javerbaum Wurgaft, a large civil litigation firm with nine (9) offices, seeks: Plaintiff Personal Injury Attorney for Northern New Jersey of...
Exciting Career Opportunities at Nuzzo & Roberts! Nuzzo & Roberts, a leading mid-sized insurance defense firm based in Cheshire, CT...
